BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Razali R, Asis H, Budiman C. Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources. Microorganisms 2021;9:2481. [PMID: 34946083 DOI: 10.3390/microorganisms9122481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Ashraf H, Dilshad E, Afsar T, Almajwal A, Shafique H, Razak S. Molecular Screening of Bioactive Compounds of Garlic for Therapeutic Effects against COVID-19. Biomedicines 2023;11. [PMID: 36831179 DOI: 10.3390/biomedicines11020643] [Reference Citation Analysis]
2 Cheohen CFAR, Esteves MEA, da Fonseca TS, Leal CM, Assis FLF, Campos MF, Rebelo RS, Allonso D, Leitão GG, da Silva ML, Leitão SG. In silico screening of phenylethanoid glycosides, a class of pharmacologically active compounds as natural inhibitors of SARS-CoV-2 proteases. Comput Struct Biotechnol J 2023;21:1461-72. [PMID: 36817956 DOI: 10.1016/j.csbj.2023.02.020] [Reference Citation Analysis]
3 Stefani C, Fantoni T, Bissoli M, Thomas J, Ruggiero A. HIV and SARS-CoV-2 Co-Infection: From Population Study Evidence to In Vitro Studies. Life (Basel) 2022;12. [PMID: 36556453 DOI: 10.3390/life12122089] [Reference Citation Analysis]
4 Akinosoglou K, Schinas G, Gogos C. Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Viruses 2022;14. [PMID: 36423149 DOI: 10.3390/v14112540] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Razali R, Fahrudin FA, Subbiah VK, Takano K, Budiman C. Heterologous Expression and Catalytic Properties of Codon-Optimized Small-Sized Bromelain from MD2 Pineapple. Molecules 2022;27:6031. [DOI: 10.3390/molecules27186031] [Reference Citation Analysis]
6 Halimi M, Bararpour P. Natural inhibitors of SARS-CoV-2 main protease: structure based pharmacophore modeling, molecular docking and molecular dynamic simulation studies. J Mol Model 2022;28. [DOI: 10.1007/s00894-022-05286-6] [Reference Citation Analysis]
7 Alzyoud L, Ghattas MA, Atatreh N. Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents. DDDT 2022;Volume 16:2463-2478. [DOI: 10.2147/dddt.s370574] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Seetaha S, Khamplong P, Wanaragthai P, Aiebchun T, Ratanabunyong S, Krobthong S, Yingchutrakul Y, Rattanasrisomporn J, Choowongkomon K. KERRA, Mixed Medicinal Plant Extracts, Inhibits SARS-CoV-2 Targets Enzymes and Feline Coronavirus. COVID 2022;2:621-632. [DOI: 10.3390/covid2050046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Nocentini A, Capasso C, Supuran CT. Perspectives on the design and discovery of α-ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go? Expert Opinion on Drug Discovery. [DOI: 10.1080/17460441.2022.2052847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Jaradat A, Salameh Y, Zaid H, Shanak S. <i>In Silico</i> Evaluation for the Inhibitory Action of Curcumin Derivatives on the SARS-CoV-2 Proteins. JBM 2022;10:63-76. [DOI: 10.4236/jbm.2022.104007] [Reference Citation Analysis]